KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EPS (Weighted Average and Diluted) (2016 - 2025)

Charles River Laboratories International has reported EPS (Weighted Average and Diluted) over the past 17 years, most recently at -$5.56 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 33.33% year-over-year to -$5.56; the TTM value through Dec 2025 reached -$2.9, down 1550.0%, while the annual FY2025 figure was -$2.91, 1555.0% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$5.56 at Charles River Laboratories International, down from $1.1 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $3.65 in Q4 2022 and troughed at -$5.56 in Q4 2025.
  • A 5-year average of $1.18 and a median of $1.73 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 50.83% in 2022 and later tumbled 214.56% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at $2.67 in 2021, then surged by 36.7% to $3.65 in 2022, then decreased by 0.27% to $3.64 in 2023, then tumbled by 214.56% to -$4.17 in 2024, then plummeted by 33.33% to -$5.56 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CRL at -$5.56 in Q4 2025, $1.1 in Q3 2025, and $1.06 in Q2 2025.